Neutrophil/Leukemia‐Tropic Dual‐Drug Nanomedicine Potentiates the Treatment of Acute Myeloid Leukemia

S Shujing Yue (State Key Laboratory of Bioinspired Interfacial Materials Science and Biomedical Polymers Laboratory College of Chemistry Chemical Engineering and Materials Science Soochow University Suzhou 215123 P. R. China) Z Zhenzhen Zhai (State Key Laboratory of Bioinspired Interfacial Materials Science and Biomedical Polymers Laboratory College of Chemistry Chemical Engineering and Materials Science Soochow University Suzhou 215123 P. R. China) J Jingnan An (Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Collaborative Innovation Center of Hematology Soochow University Suzhou 215123 P. R. China) H Huanli Sun (China FAW Corporation Limited Changchun 130013 China) J Jiaying Li C Cenzhu Zhao (Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Collaborative Innovation Center of Hematology Soochow University Suzhou 215123 P. R. China) Y Yang Xu Z Zhiyuan Zhong (Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science)

Abstract

Abstract Acute myeloid leukemia (AML) poses severe clinical challenges due to its heterogeneity and the scattered nature of therapeutic targets. Moreover, suboptimal drug delivery to the bone marrow, combined with the protective effects of the niche that shelters residual leukemia cells, frequently underlies chemotherapy failure and relapse. Here, a neutrophil/leukemia‐tropic polymersome vincristine/volasertib dual‐drug nanoformulation (NLP‐Vi/Vo) is reported to selectively bind to leukemia cells and neutrophils, and to ratiometrically release clinical chemotherapeutics and a polo‐like kinase 1 inhibitor, thereby potentiating the treatment of AML. NLP‐Vi/Vo induces synergistic anti‐AML effects by sensitizing AML to chemotherapy, and homes to bone marrow by hitchhiking on neutrophils, cooperatively depleting leukemia in both the bloodstream and bone marrow. NLP‐Vi/Vo shows excellent therapeutic efficacy in malignant murine AML and human AML xenograft models. Collectively, neutrophil/leukemia‐directing dual‐drug nanomedicines offer a promising treatment strategy for AML.

Article Details

Volume / Issue Vol. 38, Issue 6
Published January 01, 2026
ISSN 0935-9648
Publisher Unknown Publisher

Journal Info

Advanced Materials

Unknown Publisher

ISSN: 0935-9648 Physical Sciences

Authors (8)

S

Shujing Yue

State Key Laboratory of Bioinspired Interfacial Materials Science and Biomedical Polymers Laboratory College of Chemistry Chemical Engineering and Materials Science Soochow University Suzhou 215123 P. R. China

Z

Zhenzhen Zhai

State Key Laboratory of Bioinspired Interfacial Materials Science and Biomedical Polymers Laboratory College of Chemistry Chemical Engineering and Materials Science Soochow University Suzhou 215123 P. R. China

J

Jingnan An

Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Collaborative Innovation Center of Hematology Soochow University Suzhou 215123 P. R. China

H

Huanli Sun

China FAW Corporation Limited Changchun 130013 China

J

Jiaying Li

C

Cenzhu Zhao

Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Collaborative Innovation Center of Hematology Soochow University Suzhou 215123 P. R. China

Y

Yang Xu

Z

Zhiyuan Zhong

Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science